Health Services Research Program, Department of Neurology, University of Michigan, Ann Arbor, MI, United States.
Veterans Affairs Healthcare System, Ann Arbor, MI, United States.
Pain. 2019 Mar;160(3):592-599. doi: 10.1097/j.pain.0000000000001439.
We aimed to investigate the pattern and utilization of neuropathic pain medications in peripheral neuropathy patients. Using a privately insured, health care claims database from 2001 to 2014, we identified a retrospective cohort of incident peripheral neuropathy patients (validated ICD-9 definition) after excluding other chronic pain conditions. Outcome measures included opioid prescriptions, chronic opioid therapy (greater than or equal to 90 days of continuous supply), guideline-recommended medications for painful peripheral neuropathy (serotonin reuptake inhibitors, tricyclic antidepressants, and gabapentinoids), and pain specialists (neurologists, physiatrists, and anesthesiologists). Multivariable logistic regression was used to evaluate associations of patient-level factors with these outcomes. The peripheral neuropathy population included 14,426 individuals with a mean (SD) age of 43.1 years (2.8) and 52.4% men followed for 3.1 (1.7) years before and 4.5 (1.4) years after the diagnosis. In this population, 65.9% received ≥1 opioid prescription, and 8.8% received chronic opioid therapy. Of those receiving chronic opioid therapy, only 26.4% received a guideline-recommended medication before chronic opioid status. For guideline-recommended medications, 35.7% received ≥1, 12.4% ≥2, and 3.8% ≥3 different medications. No patient-level factors were associated with both high opioid utilization (initiation and chronic use) and low guideline-recommended medication utilization. Pain specialists were associated with high opioid utilization and high guideline-recommended medication utilization. In conclusion, opioid initiation and transition to chronic opioid therapy are frequent in a peripheral neuropathy population despite few patients receiving more than one guideline-recommended medication. Efforts to decrease opioid utilization and increase guideline-recommended medication use are needed to improve current neuropathic pain treatment.
我们旨在研究周围神经病变患者中神经病理性疼痛药物的使用模式和利用情况。我们使用 2001 年至 2014 年的私人保险医疗保健索赔数据库,排除其他慢性疼痛疾病后,确定了一个回顾性的周围神经病变患者队列(经 ICD-9 定义验证)。结果测量包括阿片类药物处方、慢性阿片类药物治疗(连续供应大于或等于 90 天)、治疗疼痛性周围神经病变的指南推荐药物(5-羟色胺再摄取抑制剂、三环类抗抑郁药和加巴喷丁类药物)以及疼痛专家(神经病学家、理疗师和麻醉师)。多变量逻辑回归用于评估患者水平因素与这些结果的关联。周围神经病变人群包括 14426 名平均(标准差)年龄为 43.1 岁(2.8)的个体,其中 52.4%为男性,在诊断前随访 3.1 年(1.7 年),诊断后随访 4.5 年(1.4 年)。在该人群中,65.9%的人至少接受了 1 种阿片类药物处方,8.8%的人接受了慢性阿片类药物治疗。在接受慢性阿片类药物治疗的患者中,只有 26.4%在慢性阿片类药物状态之前接受了指南推荐的药物治疗。对于指南推荐的药物,35.7%的人至少接受了 1 种,12.4%的人至少接受了 2 种,3.8%的人至少接受了 3 种不同的药物。没有患者水平的因素与高阿片类药物利用率(起始和慢性使用)和低指南推荐药物利用率相关。疼痛专家与高阿片类药物利用率和高指南推荐药物利用率相关。总之,尽管很少有患者接受一种以上的指南推荐药物,但在周围神经病变患者中,阿片类药物的起始和转为慢性阿片类药物治疗仍然很常见。需要努力减少阿片类药物的使用并增加指南推荐药物的使用,以改善目前的神经病理性疼痛治疗。